Skip to content

Guideline registry — degenerative disc disease and low-back pain

Last checked: 2026-08-30

Scope

A live PubMed E-utilities title search on 2026-08-30 returned ten DDD-linked guideline records, all addressing a procedure, pain phenotype, herniation or fusion selection rather than imaging-defined DDD as one uniform condition. This registry therefore includes low-back-pain, radicular, surgical, occupational and regenerative guidance that governs how the label is used. Status reflects the issuing body’s site on the access date, not a legal determination.

Master table

Body Year Region Scope Citation / live source Status
World Health Organization 2023 Global Nonsurgical chronic primary low-back pain in primary/community care WHO publication, accessed 2026-08-30 current
NICE 2016; update 2020 England/Wales Low-back pain and sciatica, age ≥16 NG59 recommendations, accessed 2026-08-30 current; last updated 2020
VA/DoD 2022 United States Diagnosis and treatment of low-back pain VA/DoD guideline hub, accessed 2026-08-30 current; site says update in progress
North American Spine Society 2021 North America Diagnosis and treatment of adult low-back pain NASS guideline, accessed 2026-08-30 current listed document
Australian Commission on Safety and Quality in Health Care 2022 Australia New acute low-back-pain episode: assessment, management, review/referral Clinical Care Standard, accessed 2026-08-30 current; page updated 2026
American College of Occupational and Environmental Medicine 2020 United States Working-age low-back disorders; non/minimally invasive care ACOEM summary guideline, accessed 2026-08-30 current document; update cycle due/unclear
Belgian Health Care Knowledge Centre (KCE) 2017 Belgium Low-back and radicular pain KCE Report 287A, accessed 2026-08-30 aging; update project planned 2026
Danish Health Authority 2016 Denmark Recent-onset low-back pain English quick guide, accessed 2026-08-30 historical/current status unclear
German AWMF/NVL 2017 Germany Nonspecific low-back pain NVL Kreuzschmerz v2, accessed 2026-08-30 expired 2021
American College of Physicians 2017 United States Noninvasive acute, subacute and chronic nonradicular low-back pain Qaseem et al., PMID 28192789; ACP source, accessed 2026-08-30 ACP lists inactive; partially updates 2007
ACP/American Pain Society 2007 United States Diagnosis/treatment of low-back pain ACP inactive-guideline registry, accessed 2026-08-30 superseded in part → ACP 2017; inactive
North American Spine Society 2012 North America Lumbar disc herniation with radiculopathy NASS clinical-guideline registry, accessed 2026-08-30 older; remains listed
American Society of Interventional Pain Physicians 2019 United States/international Responsible use of biologics for low-back pain Navani et al., PMID 30717500; ASIPP source, accessed 2026-08-30 superseded/updated → ASIPP 2025
American Society of Interventional Pain Physicians 2025 United States/international Regenerative therapies for chronic low-back pain Manchikanti et al., PMID 41481869; ASIPP source, accessed 2026-08-30 current update
American Society of Pain and Neuroscience 2022 United States/international Interventional treatments for low-back pain Sayed et al., PMID 36510616 published guideline; 2026-08-30 PubMed sweep found no later society-wide replacement
AANS/CNS Joint Section 2014 United States Fusion procedures for lumbar degenerative disease: injection selection and economic assessment Watters et al., PMID 24980590; Kaiser et al., PMID 24980580 historical update; current supersession status unclear
Belgian KCE care pathway 2017 Belgium Multidisciplinary low-back/radicular care pathway KCE Report 295B, accessed 2026-08-30 KCE warns guideline may be obsolete after 5 years

Per-guideline entries

WHO 2023

  • Population: adults, including older adults, with chronic primary low-back pain in primary and community care.
  • Excludes: surgery and other interventions normally delivered in secondary/tertiary care; workplace interventions.
  • Contribution: global, discipline-neutral package emphasizing person-centered, coordinated combinations rather than single isolated modalities.
  • Supported directions: education/self-care, exercise, selected physical and psychological therapies, NSAIDs in appropriate contexts.
  • Against routine use: includes braces/belts, traction and opioids for most people in most contexts.
  • Evidence companion: coordinated review series (Cancelliere 2023, PMID 37991650; Verville 2023, PMID 37991647; Southerst 2023, PMID 37991651).
  • DDD boundary: does not validate an imaging-defined disc pain source.

NICE NG59 (2016; pharmacological sciatica update 2020)

  • Population: low-back pain with or without sciatica in people aged 16 and older.
  • Imaging: do not routinely image in non-specialist care; consider specialist imaging only if likely to change management.
  • Noninvasive care: tailored self-management, normal activity and group exercise; manual therapy only in a package with exercise, with or without psychological therapy.
  • Against: traction, acupuncture, several electrotherapies, spinal injections for low-back pain, chronic opioids and gabapentinoids for low-back pain.
  • Invasive: epidural local anesthetic/steroid may be considered for acute severe sciatica; fusion only in an RCT for low-back pain; do not offer disc replacement for low-back pain.
  • Status: official page says published 2016, last updated 11 December 2020.

VA/DoD 2022

  • Population: adults with low-back pain in VA/DoD systems.
  • Structure: initial evaluation and management algorithms plus 39 evidence-based recommendations.
  • Contribution: integrated diagnostic, nonpharmacologic, pharmacologic and systems guidance, with patient tools.
  • Status: the official hub was last updated in 2025 and the central guideline index in 2026 states the lower-back-pain CPG is being updated.
  • Watch: replacement version and changes to pharmacology/intervention recommendations.

NASS 2021 low-back-pain guideline

  • Scope: a defined subset of adult low-back pain; the guideline explicitly excludes some neurological deficit and below-knee leg-pain presentations.
  • Domains: diagnosis, imaging, medical/psychological, physical medicine/rehabilitation, interventional, surgical and cost-utility.
  • Contribution: spine-specialty evidence grading across the care continuum.
  • Boundary: recommendations should not be generalized to excluded radicular/neurological populations.

Australian Low Back Pain Clinical Care Standard 2022

  • Population: patients aged ≥16 with a new acute episode, with or without leg pain.
  • Eight statements: assessment, psychosocial factors, imaging stewardship, education, activity, medicines, review and referral.
  • System feature: includes 11 implementation indicators.
  • Boundary: explicitly excludes ongoing chronic-pain management, surgery indications and specific degenerative disorders.
  • Contribution: unusually strong implementation, consumer and equity framing.

ACOEM 2020

  • Population: working-age adults with acute, subacute and chronic low-back disorders.
  • Evidence base: abbreviated publication reports 121 recommendations from a larger 862-page guideline; evidence sought across DDD, radiculopathy, spondylolisthesis, facet disease, failed surgery and stenosis.
  • Contribution: work-disability, auditability and return-to-function perspective.
  • Access caveat: full guideline is tied to MDGuidelines; the official ACOEM PDF is an abbreviated peer-reviewed summary.

Belgian KCE 2017 and pathway

  • Scope: acute/chronic low-back and radicular pain with multidisciplinary input.
  • Direction: demedicalization, continued movement, selective imaging and early risk stratification.
  • Status: KCE explicitly warns its 2017 care-pathway guideline may be obsolete after five years.
  • Update: KCE’s live project page states an update is planned in 2026 because the underlying literature review is approaching ten years old.
  • Supersession chain: KCE 2017 remains the available base → KCE update project 2026 (not yet a replacement).

Danish Health Authority 2016

  • Scope: treatment of recent-onset low-back pain.
  • Contribution: national quick guide with evidence-based conservative-care recommendations.
  • Status limitation: live source resolves, but a clear current/superseded declaration was not found in this session; treat as historical pending confirmation.

German NVL Kreuzschmerz v2 (2017)

  • Scope: coordinated cross-sector care for nonspecific low-back pain.
  • Status: official AWMF page states valid through 30 December 2021; it is expired.
  • Use: historical comparison only; do not call current.
  • Watch: replacement/re-registration in AWMF.

ACP 2017 and ACP/APS 2007

  • ACP 2017: noninvasive acute/subacute/chronic nonradicular low-back pain; nonpharmacologic chronic care first, then selective medicines (PMID 28192789).
  • ACP status: the official ACP registry now places it under inactive guidelines.
  • ACP/APS 2007: broader diagnosis/treatment document; ACP says the 2017 guideline is a partial update.
  • Chain: ACP/APS 2007 → partially superseded by ACP 2017 → ACP 2017 now inactive, with no replacement identified on the live ACP page.

NASS 2012 disc herniation with radiculopathy

  • Scope: disc herniation with radiculopathy, not axial DDD.
  • Contribution: preserves the critical boundary between root disease and structural degeneration.
  • Status: still listed among completed NASS guidelines but is older than ten years; check for update before use.

ASIPP regenerative guidance 2019 → 2025

  • 2019 contribution: responsible, safe and effective biologic use; evidence and governance framing (PMID 30717500).
  • 2025 contribution: updated evidence-based recommendations for regenerative therapies (PMID 41481869).
  • Chain: ASIPP 2019 → updated/superseded by ASIPP 2025.
  • Conflict boundary: interventional-society grading may be more permissive than general low-back-pain guidelines; product-specific randomized evidence remains limited.

ASPN interventional guideline 2022

  • Scope: evidence-based assessment of established and emerging interventional treatments across low-back-pain phenotypes (Sayed 2022, PMID 36510616).
  • Contribution: places procedure-specific selection, effectiveness and safety in one interventional pathway.
  • Boundary: a procedure guideline does not validate imaging-defined DDD as a uniform diagnosis; radicular, facet, sacroiliac, vertebrogenic and discogenic evidence must remain separated.
  • Conflict: its eligible procedures and evidentiary thresholds are broader than NICE’s recommendation against spinal injections for nonspecific low-back pain.
  • Status limitation: the peer-reviewed document resolved in the live PubMed sweep; an official current/superseded declaration was not established, so no stronger currency claim is made.

AANS/CNS fusion-guideline update 2014

  • Injection/selection chapter: medial-branch ablation was suggested for 3–6 months of relief in selected nonradicular facet-mediated pain, while diagnostic medial-branch blocks were not supported as predictors of lumbar-fusion outcome (Watters 2014, PMID 24980590).
  • Economic chapter: requires preference-based quality-of-life measurement such as EQ-5D to translate cost and outcomes into QALYs; an eight-year analysis informed its historical economic comparison (Ghogawala 2014, PMID 24980580).
  • Boundary: neither chapter establishes a reliable painful-disc test or a generic fusion indication for an MRI degeneration label.
  • Status: retained as historical guidance because a live supersession chain was not verified in this session.

Agreements

Topic Broad agreement
DDD label Imaging degeneration alone does not define treatment
Assessment Screen for serious pathology and neurological deficit
Imaging Avoid routine early imaging when uncomplicated
Education Explain, reassure and support self-management
Activity Continue/restore normal activity
Exercise Structured exercise for persistent pain
Opioids Avoid routine long-term use
Radiculopathy Separate from axial pain
Surgery Requires selected phenotype and concordance
Biologics Evidence/product governance is essential

Disagreements and gaps

Topic Guideline disagreement Evidence gap
Acupuncture ACP includes as an option; NICE says do not offer Context, comparator and cost effectiveness
Manual therapy Offered alone or only in a package Active ingredient and durability
Duloxetine ACP second-line option; NICE says do not offer antidepressants for low-back pain Small effect and phenotype selection
Spinal injections NICE says do not offer for low-back pain; interventional bodies endorse selected procedures Discogenic construct and sham evidence
Fusion NICE limits to RCT for low-back pain; spine practice/guidance permits selected surgery Valid level-selection and active comparator
Disc replacement NICE says do not offer for low-back pain; device/spine evidence supports narrow DDD eligibility Lifetime device-specific net benefit
Basivertebral ablation Absent from older general guidelines Independent replication and placement in pathway
Regenerative therapy General guidelines largely omit; ASIPP offers evidence grading Product standardization and late safety
Interventional pathway ASPN/ASIPP evaluate selected procedures; NICE is substantially more restrictive for nonspecific axial pain Independent sham replication, phenotype boundaries and opportunity cost
Fusion prediction Historical AANS/CNS guidance rejects medial-branch blocks as fusion predictors; surgical selection still uses heterogeneous tests Externally validated treatment-effect model
Imaging communication Stewardship endorsed; wording rarely specified Nocebo-reducing report trials
Work participation Prominent in occupational guidance, less elsewhere Cross-system implementation

Watch list

Body/document Watch item Next check
VA/DoD low-back-pain CPG Official site says update in progress 2026 Q4
KCE Belgium Planned 2026 update project 2027 Q1
ACP Replacement for inactive 2017 guideline 2027 Q1
NICE NG59 New evidence-triggered review 2027 Q1
NASS low-back pain Revision/update status 2027 Q1
NASS disc herniation Replacement for 2012 document 2027 Q1
ACOEM Five-year comprehensive update 2027 Q1
German AWMF/NVL Replacement for expired v2 2027 Q1
Danish Health Authority Current/superseded declaration 2027 Q1
ASIPP regenerative New product-specific trials and safety updates 2027 Q1
WHO Implementation tools and updates 2027 Q1
ASPN interventional guideline Official revision or supersession statement 2027 Q1
AANS/CNS lumbar-fusion series Current replacement/supersession chain 2027 Q1

Sources checked

  • World Health Organization — “WHO guideline for non-surgical management of chronic primary low back pain in adults in primary and community care settings,” https://www.who.int/publications/i/item/9789240081789, accessed 2026-08-30.
  • NICE — “Low back pain and sciatica in over 16s: recommendations,” https://www.nice.org.uk/guidance/NG59/chapter/recommendations, accessed 2026-08-30.
  • VA/DoD — “Diagnosis and Treatment of Low Back Pain (2022),” https://www.healthquality.va.gov/guidelines/pain/lbp/index.asp, accessed 2026-08-30.
  • NASS — “Clinical Guidelines,” https://www.spine.org/Research/Clinical-Guidelines/Low-Back-Pain, accessed 2026-08-30.
  • Australian Commission on Safety and Quality in Health Care — “Low Back Pain Clinical Care Standard,” https://www.safetyandquality.gov.au/clinical-care-standards/low-back-pain, accessed 2026-08-30.
  • KCE — “Clinical guideline on low-back and radicular pain,” https://kce.fgov.be/nl/publicaties/alle-rapporten/klinische-richtlijn-rond-lage-rugpijn-en-radiculaire-pijn, accessed 2026-08-30.
  • ACOEM — “Non-Invasive and Minimally Invasive Management of Low Back Disorders,” https://acoem.org/acoem/media/News-Library/Practice-Guidelines-Non_Invasive-Low-Back-Pain-March-2020-JOEM_1.pdf, accessed 2026-08-30.
  • AWMF — “Nationale VersorgungsLeitlinie Kreuzschmerz,” https://www.awmf.org/aktuelles/awmf-aktuell/nationale-versorgungsleitlinie-kreuzschmerz-2, accessed 2026-08-30.
  • Danish Health Authority — “National clinical guideline for recent-onset low back pain,” https://sundhedsstyrelsen.dk/da/udgivelser/2016/-/media/Udgivelser/2016/NKR-l%C3%A6nderygsmerter/EN_260736-NKR---L%C3%A6ndesmerter-quickguide-english.ashx, accessed 2026-08-30.
  • ASIPP — “Regenerative Medicine Guidelines,” https://asipp.org/regenerative-medicine-guidelines/, accessed 2026-08-30.